Objective To explore the effects of ultrasound-guided thermal ablation on prognosis in patients with advanced colon adenocarcinoma (COAD) and colorectal liver metastasis (CLMs). Methods A total of 102 patients with advanced COAD and CLMs treated in the hospital were enrolled between June 2018 and June 2021. According to random number table method

they were divided into observation group and control group

51 cases in each group. The control group was treated with bevacizumab and routine chemotherapy

while observation group was additionally treated with microwave thermal ablation (MWA). The curative effect

immune function and prognosis in the two groups were compared. Results After treatment

objective remission rate (ORR) and disease control rate (DCR) in observation group were higher than those in control group (P<0.05). After treatment

levels of CD3+

CD4+ and CD8+ were decreased in both groups. The levels of CD3+

CD4+ and CD4+/CD8+ in observation group were higher than those in control group

while CD8+ was lower than that in control group (P<0.05). After treatment

there was no significant difference in adverse reactions (gastrointestinal reactions

loss of appetite

fatigue) between the two groups (P>0.05). The cumulative recurrence-free survival rate in observation group was 73.40%

significantly higher than that in control group (χ2=4.581

P=0.032). There was no significant difference in the overall survival rate between observation group and control group (χ2=1.330

P=0.249). Conclusion Ultrasound-guided thermal ablation combined with bevacizumab can effectively improve curative effect

relieve immune suppression and improve cumulative recurrence-free survival rate in patients with advanced COAD and CLMs.